Resultados de un registro prospectivo de pacientes con desórdenes hipertensivos del embarazo en un centro de la Ciudad de Buenos Aires / Results of a Prospective Registry of Patients with Hypertensive Disorders of Pregnancy in a Center of the City of Buenos Aires

RESUMEN Introducción: Los desórdenes hipertensivos del embarazo (DHE) complican el 10% de los embarazos. Son la principal causa de mortalidad materna, y requieren un equipo multidisciplinario para su abordaje. Objetivos: Cuantificar prevalencia y definir características y evolución de los DHE en un centro con un programa dedicado para su abordaje. Material y métodos: Registro continuo y prospectivo desde noviembre 2019 hasta julio 2021 que incluyó todas las pacientes con DHE (Hipertensión arterial crónica - HTAC, hipertensión gestacional - HTg, preeclampsia precoz - PEp, preeclampsia tardía - PEt, preeclampsia sobreimpuesta - PESI, y eclampsia) y que cumplieran los criterios de inclusión. Se excluyeron las pacientes sin cobertura médica que impidiera su seguimiento ambulatorio a largo plazo en la institución. Se evaluaron características basales y evolución, tratamiento y persistencia de HTA luego del puerperio. Se analizó la incidencia de retardo en el crecimiento intrauterino (RCIU), parto pretérmino, mortalidad materna y muerte neonatal dentro de los primeros 28 días de vida. Resultados: Se realizaron 5825 partos/cesáreas y se incluyeron 152 pacientes que cumplieron criterios de inclusión, con HTg (37,5%), PEp (19,7%), PEt (38,8%), PESI (3,3%)), eclampsia (0,6%). Edad media 36,4 ± 5,6 años. El 38,1% recibió aspirina. Los antihipertensivos más utilizados fueron labetalol (65,8%) y enalapril (44,1 %) en el embarazo y el puerperio respectivamente. No hubo mortalidad materna, y la neonatal fue 3,6%. La persistencia de HTA fue del 20,0% Conclusión: La preeclampsia tardía fue el DHE más frecuente en la población analizada. Más de la mitad de las pacientes que desarrollaron DHE no recibían tratamiento preventivo con aspirina, evidenciándose un déficit en la identificación de la población de riesgo. Una de cada 5 pacientes con DHE quedó con hipertensión arterial crónica luego del puerperio.

ABSTRACT Background: Hypertensive disorders of pregnancy (HDP) complicate 10% of pregnancies. They are the main cause of maternal mortality and require a multidisciplinary team to address them. Objectives: The aim of this study was to quantify the prevalence and define the characteristics and outcome of HDP in a center with a program focused on its management. Methods: This was a continuous and prospective registry from November 2019 to July 2021 that included all patients with HDP [chronic hypertension (CHT), gestational hypertension (GHT), early-onset preeclampsia (EPE), late preeclampsia (LPE), superimposed preeclampsia (SIPE) and eclampsia] who met the inclusion criteria. Patients without medical coverage that prevented long-term outpatient follow-up at the institution were excluded. Baseline characteristics and evolution, treatment and persistent HT after puerperium were evaluated. The incidence of intrauterine growth retardation (IUGR), preterm delivery, maternal mortality and neonatal death within the first 28 days of life was analyzed. Results: Among a total f 5825 deliveries/caesarean sections, 152 patients with GHT (37.5%), EPE (19.7%), LPE (38.8%), SIPE (3.3%), and eclampsia (0.6%) who met the inclusion criteria were included in the study. Mean age was 36.4±5.6 years. Aspirin was administered to 38.1% of patients. The most commonly used antihypertensive drugs were labetalol (65.8%) and enalapril (44.1%) during pregnancy and puerperium, respectively. There was no maternal mortality, and neonatal mortality was 3.6%. Persistent HT was 20.0%. Conclusion: Late preeclampsia was the most frequent HDP in the population analyzed. More than half of the patients who developed HDP did not receive preventive treatment with aspirin, showing a deficit in the identification of the population at risk. One in 5 HDP patients remained with CHTN after puerperium.

Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.

OBJECTIVES: The aim of this study was the comparison of a new double-coated paclitaxel-eluting coronary stent with bare-metal stent (BMS) in patients undergoing percutaneous coronary intervention. BACKGROUND: Stent coating with biodegradable polymers as a platform for elution of drugs has the potential for complete elution of drugs and for decreasing the risk of late complications. METHODS: Multicenter randomized trial comparing a paclitaxel-eluting stent (PES) coated with a biodegradable polymer and glycocalyx with the equivalent BMS. We randomly assigned 422 patients with de novo coronary lesions to PES (211 patients) or to BMS (211 patients). Primary end point was target vessel failure (TVF) defined as cardiac death, myocardial infarction, and target vessel revascularization. Clinical secondary end points were target vessel revascularization, target lesion revascularization, stent thrombosis (ST), and major adverse cardiovascular events (MACE). Angiographic secondary end points were late loss and binary restenosis. RESULTS: At 1 year of follow-up, TVF rate was 9.5% in the PES group and 17.1% in the BMS group (P=0.02), and MACE rate was 10% in PES and 19% in BMS arm (P=0.009). All other secondary end points were reached but ST. ST rate was low and similar in both study arms. CONCLUSIONS: The study shows that patients treated with PES with dual coating technology had significantly lower incidence of TVF and MACE than those treated with BMS design; however, longer follow-up should be necessary to assess true advantages of this technology compared with the previous one.

Embolectomía percutánea reolítica en la tromboembolia pulmonar masiva / Percutaneous Rheolytic Embolectomy for Massive Pulmonary Embolism

La tromboembolia de pulmón es una patología cardiovascular frecuente, con una incidencia de 1/1.000 en los Estados Unidos y una mortalidad que alcanza el 15% en los tres meses siguientes a su diagnóstico. Esta mortalidad aumenta cinco veces en los pacientes que desarrollan shock. A pesar de su incidencia y morbimortalidad elevadas, el tratamiento habitual no ha variado sustancialmente en los últimos años y aun a pesar de los avances en las terapias con trombolíticos o la endarterectomía quirúrgica, la tasa de mortalidad se mantiene muy elevada en los pacientes con tromboembolia pulmonar masiva. Recientemente se ha comenzado a utilizar terapias de trombectomía percutánea, que abren una nueva opción terapéutica que debe considerarse si se dispone de los medios necesarios. En esta presentación se describen dos casos de tromboembolia pulmonar masiva tratados con trombectomía reolítica.

Pulmonary embolism (PE) is a common cardiovascular disease with an incidence of 1/1000 in the United States and a mortality rate of 15% three months after been diagnosed. Mortality is five times greater in patients with shock. Despite its high incidence, morbidity and mortality, the treatment has not varied in the last years, and in patients with massive PE mortality still remains high even with the current improvements in thrombolytic therapy or surgical endarterectomy. The recent introduction of percutaneous thrombectomy techniques has opened a new therapeutic option that should be considered when available. We describe two case reports of massive pulmonary embolism treated with rheolytic thrombectomy.

Early assessment of myocardial viability by the use of delayed enhancement computed tomography after primary percutaneous coronary intervention.

OBJECTIVES: We sought to explore the relationship between established parameters of reperfusion and the extent of myocardial damage measured by the delayed enhancement (DE) of iodinated contrast by multidetector computed tomography (MDCT) immediately after primary percutaneous coronary intervention (PCI). BACKGROUND: Early detection of myocardial viability should be valuable for risk stratification of patients with reperfused acute myocardial infarction (AMI). METHODS: Consecutive patients without a history of previous AMI who underwent primary PCI for an ST-segment elevation AMI were examined by DE-MDCT without an additional contrast injection immediately after completion of PCI. No medication was administrated to lower the heart rate. Dose modulation lead to an approximate mean radiation dose of 5.5 mSv. RESULTS: Thirty patients constituted the study population. Mean age was 61.4 +/- 15.6 years, 24 (80%) were men, and 4 (13%) were diabetic. Although post-procedural Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 was achieved in all patients, DE was detected in 14 (47%) patients. Age, sex, hypertension, diabetes, smoking history, serum creatinine levels, and pain duration were not associated with the presence of DE. Door-to-balloon time (DE 70.3 +/- 33.6 min vs. non-DE 98.3 +/- 70.7 min, p = 0.19) and lesion crossing time (DE 18.6 +/- 11.4 min vs. non-DE 16.4 +/- 9.6 min, p = 0.58) did not differ between groups. The TIMI myocardial perfusion grade (0 to 1 vs. 2 to 3) after stent implantation and electrocardiogram ST-segment resolution (<50% or >/=50%) were associated with the presence of DE (p = 0.001 and p = 0.02, respectively). Pre-discharge left ventricular ejection fraction was lower in DE than in non-DE patients (44.6 +/- 12.4% vs. 54.1 +/- 10.3%, respectively, p = 0.05). Hospitalization days (DE 5.6 +/- 3.8 vs. non-DE 4.8 +/- 1.0, p = 0.41) and 6-month cardiac events (DE 3 of 14 vs. non-DE 1 of 16, p = 0.22) did not differ between groups. CONCLUSIONS: Early detection of myocardial viability immediately after primary PCI by the use of DE-MDCT is related to clinical and angiographic parameters of myocardial reperfusion.

Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry.

AIMS: Long-term benefit from coronary revascularization with drug-eluting stents (DES) relative to bare metal stents (BMS) and coronary artery bypass grafting (CABG) has not been established. One year follow-up of the ERACI III registry study showed better outcome with DES. To compare major adverse cardiac and cerebrovascular event (MACCE) rates in patients with multivessel cardiovascular disease (CVD) who received DES with those patients treated with BMS or CABG in the ERACI II trial. METHODS AND RESULTS: Patients with multivessel CVD who met the ERACI II trial, clinical and angiographic inclusion criteria were treated with DES and enrolled in the ERACI III registry. The primary endpoint was 3-year MACCE. ERACI III-DES patients (n = 225) were compared with the BMS (n = 225) and CABG (n = 225) arms of ERACI II. Patients treated with DES were older, more often smokers, more often high risk by euroSCORE and less frequently had unstable angina. They also had higher incidence of type C lesions and received more stents than the BMS-treated cohort. Three year MACCE was lower in ERACI III-DES (22.7%) than in ERACI II-BMS (29.8%, P = 0.015), mainly reflecting less target vessel revascularization (14.2 vs. 24.4%, P = 0.009). MACCE rates at 3 years were similar in DES and CABG-treated patients (22.7%, P = 1.0), in contrast to results at 1 year (12 vs. 19.6%, P = 0.038). MACCE rates in ERACI III-DES were higher in diabetics (RR 0.81, 0.66-0.99; P = 0.018). Death or non-fatal MI at 3 years trended higher in the DES (10.2%) than BMS cohort (6.2%, P = 0.08) and lower than in CABG patients (15.1%, P = 0.07). Sub-acute late-stent thrombosis (LST) (>30 days) occurred in nine DES patients and no BMS patients (P = 0.008). CONCLUSION: In patients with multivessel CVD, the initial advantage for PCI with DES over CABG observed at 1 year was not apparent by 3 years. Furthermore, despite continued lower incidence of MACCE, initial advantage over BMS appeared to decrease with time. LST occurred more frequent in DES-treated patients.

Resultados de la angioplastia coronaria con colocación de stent: seguimiento alejado. Registro CONAREC V / Long-term follow-up results in coronary angioplasty with stent implant. CONAREC V registry

El stent es un dispositivo útil para mejorar los resultados de la angioplastia convencional. Si bien su utilización es amplia, no se conocen con precisión sus resultados a largo tiempo en nuestro país. Del registro CONAREC V se analizaron 1023 pacientes con éxito clínico y seguimiento disponible. Se compararon los grupos de pacientes tratados mediante angioplastia con stent y sin stent. Durante el seguimiento se observó una incidencia menor de eventos totales en el grupo stent, sin que se hallaran diferencias significativas en las complicaciones mayores ni en la necesidad de nuevos procedimientos de revascularización

Resultados de la angioplastia coronaria con colocación de stent: seguimiento alejado. Registro CONAREC V / Long-term follow-up results in coronary angioplasty with stent implant. CONAREC V registry

El stent es un dispositivo útil para mejorar los resultados de la angioplastia convencional. Si bien su utilización es amplia, no se conocen con precisión sus resultados a largo tiempo en nuestro país. Del registro CONAREC V se analizaron 1023 pacientes con éxito clínico y seguimiento disponible. Se compararon los grupos de pacientes tratados mediante angioplastia con stent y sin stent. Durante el seguimiento se observó una incidencia menor de eventos totales en el grupo stent, sin que se hallaran diferencias significativas en las complicaciones mayores ni en la necesidad de nuevos procedimientos de revascularización (AU)